SB 239063

Drug Profile

SB 239063

Alternative Names: 239063

Latest Information Update: 09 Feb 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Imidazoles; Neuroprotectants; Pyrimidines
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Stroke

Most Recent Events

  • 09 Feb 2006 No development reported - Preclinical for Asthma in USA (PO)
  • 22 Jun 2004 Preclinical trials in Asthma in USA (PO)
  • 22 Jun 2004 Data presented at the 100th International Conference of the American Thoracic Society (ATS-2004) have been added to the Obstructive Airways Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top